Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral Rebound During Treatment Interruption

被引：0

作者：

Mendoza, Pilar ^{[1
]}

Gruell, Henning ^{[2
]}

Lu, Ching-Lan ^{[1
]}

Butler, Allison ^{[1
]}

Pai, Joy ^{[1
]}

Nogueira, Lilian ^{[1
]}

Oliveira, Thiago Y. ^{[1
]}

Lorenzi, Julio C. C. ^{[1
]}

Cohen, Yehuda Z. ^{[1
]}

Millard, Katrina ^{[1
]}

Unson-O'Brien, Cecille ^{[1
]}

Belblidia, Shiraz A. ^{[1
]}

Patel, Roshni ^{[1
]}

Witmer-Pack, Maggi ^{[1
]}

Schimeliovich, Irina ^{[1
]}

Jankovic, Mila ^{[1
]}

Seaman, Michael S. ^{[3
]}

Klein, Florian ^{[2
]}

Caskey, Marina ^{[1
]}

Nussenzweig, Michel C. ^{[1
]}

机构：

[1] Rockefeller Univ, New York, NY USA

[2] Univ Cologne, Cologne, Germany

[3] Beth Israel Deaconess Med Ctr, Boston, MA USA

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2018年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

OA08.01

引用

页码：34 / 34

页数：1

共 30 条

[1] HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid
Joshua A. Horwitz
Yotam Bar-On
Edward F. Kreider
Ching-Lan Lu
Julio C. C. Lorenzi
Anna Feldmann
Malte Braunschweig
Lilian Nogueira
Thiago Oliveira
Irina Shimeliovich
Roshni Patel
Leah Burke
Yehuda Z. Cohen
Sonya Hadrigan
Allison Settler
Maggi Witmer-Pack
Anthony P. West, Jr.
Boris Juelg
Tibor Keler
Thomas Hawthorne
Barry Zingman
Roy M. Gulick
Nico Pfeifer
Gerald H. Learn
Michael S. Seaman
Pamela J. Bjorkman
Florian Klein
Sarah J. Schlesinger
Bruce D. Walker
Beatrice H. Hahn
Michel C. Nussenzweig
Marina Caskey
Nature, 2016, 535 : 556 - 560
[2] HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Scheid, Johannes F.
Horwitz, Joshua A.
Bar-On, Yotam
Kreider, Edward F.
Lu, Ching-Lan
Lorenzi, Julio C. C.
Feldmann, Anna
Braunschweig, Malte
Nogueira, Lilian
Oliveira, Thiago
Shimeliovich, Irina
Patel, Roshni
Burke, Leah
Cohen, Yehuda Z.
Hadrigan, Sonya
Settler, Allison
Witmer-Pack, Maggi
West, Anthony P., Jr.
Juelg, Boris
Keler, Tibor
Hawthorne, Thomas
Zingman, Barry
Gulick, Roy M.
Pfeifer, Nico
Learn, Gerald H.
Seaman, Michael S.
Bjorkman, Pamela J.
Klein, Florian
Schlesinger, Sarah J.
Walker, Bruce D.
Hahn, Beatrice H.
Nussenzweig, Michel C.
Caskey, Marina
NATURE, 2016, 535 (7613) : 556 - +
[3] Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons
Tebas, Pablo
Lynn, Kenn
Azzoni, Livio
Cocchella, Giorgio
Papasavvas, Emmanouil
Fair, Matthew
Karanam, Brijesh
Sharma, Paridhima
Reeves, Jacqueline D.
Petropoulos, Christos J.
Lalley-Chareczko, Linden
Kostman, Jay R.
Short, William
Mounzer, Karam
Montaner, Luis J.
AIDS, 2023, 37 (08) : 1203 - 1207
[4] Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Cohen, Yehuda Z.
Butler, Allison L.
Millard, Katrina
Witmer-Pack, Maggi
Levin, Rebeka
Unson-O'Brien, Cecilia
Patel, Roshni
Shimeliovich, Irina
Lorenzi, Julio C. C.
Horowitz, Jill
Walsh, Stephen R.
Lin, Shu
Weiner, Joshua A.
Tse, Anna
Sato, Alicia
Bennett, Chelsey
Mayer, Bryan
Seaton, Kelly E.
Yates, Nicole L.
Baden, Lindsey R.
deCamp, Allan C.
Ackerman, Margaret E.
Seaman, Michael S.
Tomaras, Georgia D.
Nussenzweig, Michel C.
Caskey, Marina
PLOS ONE, 2019, 14 (08):
[5] A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117
Zacharopoulou, Panagiota
Ansari, M. Azim
Frater, John
CURRENT OPINION IN HIV AND AIDS, 2022, 17 (06) : 352 - 358
[6] HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Schoofs, Till
Klein, Florian
Braunschweig, Malte
Kreider, Edward F.
Feldmann, Anna
Nogueira, Lilian
Oliveira, Thiago
Lorenzi, Julio C. C.
Parrish, Erica H.
Learn, Gerald H.
West, Anthony P., Jr.
Bjorkman, Pamela J.
Schlesinger, Sarah J.
Seaman, Michael S.
Czartoski, Julie
McElrath, M. Juliana
Pfeifer, Nico
Hahn, Beatrice H.
Caskey, Marina
Nussenzweig, Michel C.
SCIENCE, 2016, 352 (6288) : 997 - 1001
[7] Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
Cohen, Yehuda Z.
Lorenzi, Julio C. C.
Krassnig, Lisa
Barton, John P.
Burke, Leah
Pai, Joy
Lu, Ching-Lan
Mendoza, Pilar
Oliveira, Thiago Y.
Sleckman, Christopher
Millard, Katrina
Butler, Allison L.
Dizon, Juan P.
Belblidia, Shiraz A.
Witmer-Pack, Maggi
Shimeliovich, Irina
Gulick, Roy M.
Seaman, Michael S.
Jankovic, Mila
Caskey, Marina
Nussenzweig, Michel C.
JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (09): : 2311 - 2324
[8] Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Hurst, Jacob
Hoffmann, Matthias
Pace, Matthew
Williams, James P.
Thornhill, John
Hamlyn, Elizabeth
Meyerowitz, Jodi
Willberg, Chris
Koelsch, Kersten K.
Robinson, Nicola
Brown, Helen
Fisher, Martin
Kinloch, Sabine
Cooper, David A.
Schechter, Mauro
Tambussi, Giuseppe
Fidler, Sarah
Babiker, Abdel
Weber, Jonathan
Kelleher, Anthony D.
Phillips, Rodney E.
Frater, John
NATURE COMMUNICATIONS, 2015, 6
[9] Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Jacob Hurst
Matthias Hoffmann
Matthew Pace
James P. Williams
John Thornhill
Elizabeth Hamlyn
Jodi Meyerowitz
Chris Willberg
Kersten K. Koelsch
Nicola Robinson
Helen Brown
Martin Fisher
Sabine Kinloch
David A. Cooper
Mauro Schechter
Giuseppe Tambussi
Sarah Fidler
Abdel Babiker
Jonathan Weber
Anthony D. Kelleher
Rodney E. Phillips
John Frater
Nature Communications, 6
[10] Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges
Liu, Zhi-Jun
Bai, Jing
Liu, Feng-Li
Zhang, Xiang-Yang
Wang, Jing-Zhang
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 52 : 44 - 50

← 1 2 3 →